Skip to site menu Skip to page content
17 Apr 2026

First patient receives JANX014 dose in Janux’s trial for mCRPC

Janux Therapeutics has announced the dosing of its first patient in a Phase I clinical trial evaluating JANX014 for metastatic castration-resistant prostate cancer (mCRPC). The multicentre, first-in-human, open-label trial will…

16 Apr 2026

Precision receives CTA approval to expand ELIMINATE-B study

Precision BioSciences has received clinical trial application (CTA) approval to expand its global ELIMINATE-B study of PBGENE-HBV, an in vivo gene editing therapy for chronic hepatitis B. The regulatory clearance…

15 Apr 2026

GlycoNex secures Japan’s PMDA approval for GNX1021 Phase I trial

GlycoNex has received Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approval to commence a first-in-human Phase I clinical trial of GNX1021, its lead antibody-drug conjugate (ADC) candidate, for advanced gastrointestinal…

[ajax_load_more post_type="post" taxonomy="category" taxonomy_terms="company-news, contract-news, deal-news, industry-news, news" taxonomy_operator="IN" images_loaded="true" posts_per_page="20" offset="7" pause="true" scroll="false" button_label="Load More Stories"]